Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment

Elsberger, B., Paravasthu, D.M., Tovey, S.M. and Edwards, J. (2012) Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. Journal of Cancer Research and Clinical Oncology, 138(2), pp. 327-332. (doi: 10.1007/s00432-011-1096-8)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1007/s00432-011-1096-8

Abstract

<b>Background</b> <p>Src kinase, a non-receptor tyrosine kinase, is overexpressed and highly activated in a number of human cancers and appears to show a significant relationship with breast cancer progression. Recent in vitro studies have suggested that Src kinase may be involved in tamoxifen resistance.</p> <b>Methods</b> <p>Immunohistochemistry was performed on 392 resected breast cancers using an antibody to c-Src. Expression was assessed using the weighted histoscore method.</p> <b>Results</b> <p>Forty-five percentage of breast tumours exhibited nuclear, 46% cytoplasmic and 7% membrane expression. Lymph node positivity correlated with cytoplasmic c-Src tumour expression levels (P < 0.001). Nuclear c-Src correlated negatively with cytoplasmic and membrane c-Src expression (P < 0.001, P = 0.005). High expression levels of cytoplasmic c-Src was associated with worse disease-specific survival (P = 0.026) after completing 5 years of tamoxifen therapy. However, high expression of c-Src at any cellular location did not show any association with de novo relapse on tamoxifen (c-Src nuc P = 0.906, c-Src cyto P = 0.735 and c-Src memb P = 0.791)</p> <b>Conclusions</b> <p>No translational evidence was found in this study to support a role for Src kinase in developing de novo tamoxifen resistance. However, based on our findings on late clinical outcome, patients with high cytoplasmic c-Src may be selected for continuing endocrine therapy to prevent worsening prognosis.</p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Elsberger, Miss Beatrix and Edwards, Professor Joanne
Authors: Elsberger, B., Paravasthu, D.M., Tovey, S.M., and Edwards, J.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Journal of Cancer Research and Clinical Oncology
ISSN:0171-5216
ISSN (Online):1432-1335

University Staff: Request a correction | Enlighten Editors: Update this record